
-
Instil Bio NASDAQ:TIL Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer.
Location: | Website: instilbio.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
56.97M
Cash
113.3M
Avg Qtr Burn
-13.92M
Short % of Float
24.12%
Insider Ownership
12.76%
Institutional Own.
79.94%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AXN-2510/IMM2510 + chemotherapy Details Cancer, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
AXN-2510 (formerly SYN-2510) /IMM2510 Details Cancer, Non-small cell lung carcinoma, Solid tumor/s | Phase 1 Data readout | |
ITIL-306 Details Cancer, Non-small cell lung carcinoma, Ovarian cancer, Renal cell carcinoma | Failed Discontinued | |
ITIL-168 Details Cancer, Melanoma | Failed Discontinued |